(No ratings)
Dr. Vidya Premanand Nagrale, MD is a molecular genetic pathologist in Chicago, IL specializing in molecular genetic pathology, dermatopathology, hematopathology and cytopathology. She graduated from Seth G.S. Medical College in 1996 and has 30 years of experience. Dr. Vidya Premanand Nagrale, MD is affiliated with UTMB Health.
Dr. Vidya Premanand Nagrale, MD graduated from Seth G.S. Medical College in 1996. She completed residency at University of Illinois at Chicago Affiliated Hospitals. She is certified by the Certifications: American Board of Pathology, Anatomic Pathology and has a state license in Illinois.
Medical School: Seth G.S. Medical College (1996)
Residency: University of Illinois at Chicago Affiliated Hospitals (2014)
Board Certification: Certifications: American Board of Pathology, Anatomic Pathology
Licensed In: Illinois
Dr. Vidya Premanand Nagrale, MD is associated with these hospitals and organizations:
Dr. Vidya Premanand Nagrale, MD does not have any reviews yet, be the first to leave a review of Dr. Vidya Premanand Nagrale, MD here: Leave a Review
(No ratings)
These charts describe general payments received by Dr. Vidya Premanand Nagrale, MD. Doctors may receive payments for a number of reasons, including meal compensation, travel compensation, and consulting.
| E.R. Squibb & Sons, L.L.C. |
$40
EMPLICITI $23 |
OPDIVO $18 |
|---|---|---|
| Millennium Pharmaceuticals, Inc. |
$25
NINLARO $25 |
|
| Alexion Pharmaceuticals, Inc. |
$13
SOLIRIS $13 |
| Food and Beverage | $78 |
|---|
Dr. Vidya Nagrale's medical specialty is molecular genetic pathology, cytopathology, and dermatopathology. She attended Seth G.S. Medical College and then went on to complete her residency at the University of Iowa Hospitals & Clinics, a hospital affiliated with SUNY, University at Buffalo, and a hospital affiliated with the University of Illinois at Chicago. Dr. Nagrale's professional affiliations include UTMB Health and Roswell Park Comprehensive Cancer Center. UTMB Health reports that she is not accepting new patients.